OUR THESIS

Lifeblood Capital fundamentally takes an opportunistic approach toward investments. 

Our main objective is to further the MedTech entrepreneurial community. 

We understand that capital and talent are the lifeblood that gives birth to the most impactful change in society – improving lives holistically. 

We are thankful for the opportunity to meet and support the most amazing entrepreneurs and venture investors who make their life purpose to improve healthcare.

Galen Robotics

SURGERY

Extending Surgical Assistance into Microsurgery. Galen Robotics aims at filling gaps left by other surgical robotic technologies, with a focus on unserved applications in microsurgery, digital surgery, and robotic surgery.

VESTECK, Inc.

SUTURES

The VESTECK catheter sutures endovascular aortic repair grafts to the aorta, eliminating graft migration and leaks that lead to complex, expensive repairs

Vonova

MINIMALLY INVASIVE BRAIN INTERFACE

Vonova is developing the less invasive pathway to the brain surface for the treatment of drug-resistant epilepsy and other neurological disorders. The novel system employs the latest in catheter-based technology to interface with the brain surface for diagnostic and therapeutic applications.

Von Medical, Inc

SURGERY

Von Medical designs develops, and conducts research on cutting-edge endovascular technology to safeguard and improve patient lives while minimizing procedural complexity.

Vivifi Medical

SUTURES

Vivifi’s mission is to improve the quality of life of patients with Male Infertility and BPH by ending recurrency. Vivifi has developed the world’s first suture-less solution for immediate and long- lasting reversal of varicocele, the Calexis-Lap Device. Vivifi aims to surpass the current standard of care for BPH and Male infertility in order to provide freedom and independence to patients.

Cellular Vehicles

CELL & GENE THERAPY

Cellular Vehicles is building novel products to control and standardize ‘last mile’ Cell and Gene Therapy handling, preparation, and administration. The Odyssey System, an automation platform, introduces control and standardization to this “last mile” process, while lowering costs. The platform gives CGT developers control over how their drugs are delivered to patients and increases the pace of new site onboarding and patient enrollment. For HCPs, the Odyssey System enables simplification of training, and reduction of CGT preparation and overhead costs.

Opal Ventures

VC/PE

Opal Ventures backs startups that empower people to live healthier, happier, and more productive lives.

Building a team?

Scroll to Top